Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries and Active Biotech have released initial results from the two-year Phase III Allegro study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6mg daily oral Laquinimod experienced reduction in annualised relapse rate compared to placebo, the trial met its primary endpoint.
Subscribe to our email newsletter
Additional clinical endpoints, including reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.
In the trial, Laquinimod was safe and well-tolerated.
In addition to the ongoing MS clinical studies, Laquinimod is currently in Phase II development for crohn’s disease and Lupus, and is being studied in other autoimmune diseases.
Principal investigator Giancarlo Comi said that this pivotal study met its primary endpoint while maintaining a very good safety profile.
"Laquinimod demonstrated a significant reduction in the progression of disability which may be explained by its unique mechanism of action that includes neuroprotective properties,"Comi said.